Skip to main content
. 2023 Mar 15;133(6):e166032. doi: 10.1172/JCI166032

Figure 3. Temporal evolution of anti-N, anti-S, and anti-RBD serology titers in patients receiving mAb therapies.

Figure 3

(A) Natural immunity was assessed based on anti-N titers, revealing a gradual increase through D28. High anti-S and anti-RBD titers due to therapeutic mAb administration persisted from D2 to D28 in patients in all treatment groups. (B) Similarly, high anti-S and anti-RBD titers were observed in patients carrying Omicron subvariants (BA.1, BA1+R346K, or BA.2) receiving sotrovimab monotherapy. Red, green, and blue dotted lines indicate SARS-CoV-2 WHO reference standard values for low, medium, and high antibody titers, respectively. Line graphs in A and B represent conditional means and shaded areas displaying 95% CIs for all measured time points. Linear mixed models were utilized to investigate evolution of antibody titers over time for different mAbs, with asterisks indicating significance of the slopes of the curves. **P < 0.01, ***P < 0.001. For more details on serology in patients with or without vaccination and sample numbers, see Supplemental Table 5 and Supplemental Figure 7.